In the news release, Patrick G. LePore Elected to Board of Directors of Par Pharmaceutical Companies, Inc., issued earlier today by Par Pharmaceutical Companies, Inc. over PR Newswire, we are advised by the company that the second sentence in the boilerplate should read "In 2005, Par received approval for and introduced Megace(R) ES, its first branded pharmaceutical product, and expects to launch a second in 2006," rather than "In 2005, Par received approval for and introduced Megace(R) ES, its first branded pharmaceutical product, and will launch Cesamet(TM), its second branded product, in July 2006," as originally issued inadvertently. Cesamet (TM) is a product of Valeant Pharmaceuticals International. DATASOURCE: Par Pharmaceutical Companies, Inc. Web site: http://www.parpharm.com/

Copyright